Proteomics is moving beyond broad discovery to deliver real-time, clinically meaningful insights. At the forefront is Quanterix’s Simoa® digital immunoassay technology, enabling ultra-sensitive, reproducible detection of low-abundance biomarkers in areas like neurology, oncology, and immunology.
With over 3,000 peer-reviewed publications, Simoa supports earlier disease detection, improved trial design, and deeper biological insight.
Download this whitepaper to learn:
- Why traditional proteomic tools fall short in clinical applications
- How Simoa achieves unmatched sensitivity and reproducibility
- How proteomics and genomics work together in multi-omics strategies